Determination of Patents and Other Intellectual Property. Notwithstanding the foregoing, any dispute relating to the determination of validity of claims, infringement or claim interpretation relating to a Party's patents shall be submitted exclusively to federal court.
Determination of Patents and Other Intellectual Property. Any dispute relating to the determination of validity of a Party’s Patents or other issues relating solely to a Party’s intellectual property shall be submitted exclusively to the federal court located in the location of the defendant, and the Parties hereby consent to the jurisdiction and venue of such court.
Determination of Patents and Other Intellectual Property. Notwithstanding Article 10.1, any dispute relating to the ownership, scope, validity or infringement of intellectual property rights (including any determination of validity of claims, infringement or claim interpretation relating to Licensor’s Patent Rights) shall be submitted exclusively to the courts.
Determination of Patents and Other Intellectual Property. Any dispute relating to the determination of ownership, validity or infringement by the other Party of a Party's patents shall be submitted exclusively to the federal courts located in the Southern District of New York, and the Parties hereby consent to the jurisdiction and venue of such court.
Determination of Patents and Other Intellectual Property. Notwithstanding the foregoing, any dispute relating to the determination of validity of claims, infringement or claim interpretation relating to Micrologix’s Patents shall be submitted exclusively to the federal courts.
Determination of Patents and Other Intellectual Property. Notwithstanding the foregoing, any dispute relating to the determination of validity of claims, infringement or claim interpretation relating to Santee’s Patent Rights shall be submitted exclusively to the courts.
Determination of Patents and Other Intellectual Property. Notwithstanding the foregoing, any dispute relating to the determination of validity of claims, infringement or claim interpretation relating to Cardiome's Patents or Fujisawa's Patents or Fujisawa's Marks shall be submitted exclusively to the federal courts.
Determination of Patents and Other Intellectual Property. Notwithstanding the foregoing, any dispute between the parties relating to the determination of validity of a party's patents or other issues relating to a party's intellectual property shall be submitted exclusively to the federal court located in San Diego, California (if such dispute is initiated by Corixa) or in Seattle Washington (if such dispute is initiated by Gen-Probe), or to a state court in such jurisdiction if the applicable rules of civil procedure preclude federal court jurisdiction, and the parties hereby consent to the jurisdiction and venue of such courts.
Determination of Patents and Other Intellectual Property. Notwithstanding the foregoing, any dispute relating to the determination of validity of a Party’s Patents or other issues relating to a Party’s intellectual property shall be submitted to a court of competent jurisdiction (a) selected by Licensee, in the case of any such dispute involving any patent or other intellectual property of Licensee, and (b) selected by Lonza, in the case of any such dispute involving any patent or other intellectual property of Lonza.
Determination of Patents and Other Intellectual Property. Notwithstanding the foregoing, any dispute relating to the determination of validity of a Party's patents or other issues relating to a Party's intellectual property shall be submitted exclusively to the federal court located in the jurisdiction of the defendant, or to a state court in such jurisdiction if the applicable rules of civil procedure preclude federal court jurisdiction, and the Parties hereby consent to the jurisdiction and venue of such courts. * Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. The omitted portions of this exhibit have been filed separately with the SEC.
